Sector: Health Care
Director information for SOLVENTUM CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Amy A. Wendell | Former SVP, Strategy and Business Development and Licensing, Covidien Inc.; Director | 65 | ["Former SVP, Strategy and Business Development and Licensing, Covidien Inc.", "Over 30 years of experience in strategic leadership roles and member of multiple boards at healthcare and medical device companies", "Deep knowledge through executive and board experience of financial valuation and portfolio optimization", "Service on the boards and in senior strategy roles at global healthcare and medical device companies", "Extensive and thorough experience in guiding companies undergoing significant transitions, including M&A, as well as portfolio management and spin-offs", "Considerable experience overseeing acquisition and portfolio management of science and research companies", "Strategic responsibility for large multinational companies operating in regulated industries; Roles in product development and licensing and distribution", "Oversight in multiple roles of revenue growth and margin enhancement for large global companies", "Significant experience with mergers and acquisitions as well as divestitures for multiple public and private companies with oversight over strategic risk", "Leadership of large teams particularly in performance and advancement; Roles on public company boards with oversight over human capital management"] | ["GC", "STQC", "Governance", "Science, Technology and Quality"] | 2026 |
| Bryan Hanson | Chief Executive Officer | 59 | ["Over 30 years of experience in leadership roles at medical device companies", "Healthcare executive experience, including as CEO of a global medical technology company", "Completion of executive leadership programs at Kellogg School of Management and Harvard Business School", "Significant experience in financial management as a seasoned executive during periods of growth and portfolio optimization", "Service in multiple senior executive roles at global healthcare companies", "Extensive experience in guiding companies through significant transitions, as well as in strategic planning and mergers and acquisitions", "Deep experience as head of medical device businesses", "Substantial experience as chief executive and board member at multiple companies with oversight over risk", "Senior executive leadership expertise"] | [] | 2026 |
| Carlos Albán | Former Vice Chairman, Chief Commercial Officer, Abbvie Inc.; Director | 63 | ["Over 30 years of experience in pharmaceutical company roles overseeing commercial operations, growth, and development", "Pharmaceutical executive experience including as Chief Commercial Officer during a period of significant expansion", "Extensive experience in roles at global healthcare companies responsible for multiple worldwide regions", "Deep experience in guiding companies undergoing significant transitions, including recently spun-off companies, as well as in M&A transactions", "Significant experience as Chief Commercial Officer and head of pharmaceutical units at pharmaceutical development companies", "Success guiding strong business growth and sales of leading pharmaceutical products"] | ["GC", "TC", "Governance", "Talent"] | 2026 |
| Carrie S. Cox | Chair of the Board; Chair of the board | 68 | ["Former Chief Executive Officer, Humacyte, Inc.", "30 years of experience in leadership roles and member of multiple boards at healthcare companies", "Pharmaceutical and biotech executive experience including as CEO of a regenerative medicine company", "Significant experience as a seasoned executive and audit committee member", "Service on the boards and senior executive roles at global healthcare companies", "Deep experience in guiding companies undergoing significant transitions, including recently spun-off companies, as well as in M&A transactions", "Deep experience at head of drug and biotech development companies; Responsible for significant capital and R&D investments", "Management responsibility of a large multinational company operating in a regulated industry", "Roles including oversight of sales plans, marketing and brand for large global companies", "Significant experience as chair of board at multiple public and private companies with oversight over risk", "Notable compensation committee expertise"] | ["TC", "STQC", "Talent", "Science, Technology and Quality"] | 2026 |
| Darryl L. Wilson | Former Vice President, Commercial; Director | 62 | ["Former Vice President, Commercial, GE Power, General Electric Company", "Global perspective on business operations", "Commercial management", "Manufacturing and mergers and acquisitions", "Significant integration, cost savings, and business growth initiatives", "Oversaw major restructurings", "MBA in Marketing from Indiana University", "BA in Business Administration from Baldwin Wallace College", "Chief Commercial Officer of multiple major divisions of a large multinational industrial company", "Strong oversight expertise and experience in finance and financial markets", "Extensive experience in senior oversight roles at global conglomerates", "Experience in divestitures, mergers and acquisitions", "Experience overseeing product development and commercialization", "Management responsibility over product quality control and safety systems", "Driving business growth in multiple segments and regions", "Substantial experience as board member at multiple public and private companies", "Oversaw large teams in multiple segments and global operations"] | ["AC", "TC", "Audit", "Talent"] | 2026 |
| Dr. Bernard A. Harris Jr. | Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.; Director | 69 | ["Deep science, technology, and medical background", "Leadership experience in business operations and investment", "Extensive and unique medical and healthcare experience", "Experience on the board of a healthcare services company", "Service on the boards of global companies and international space missions", "Oversight experience in guiding companies undergoing significant transitions", "Substantial experience as a research, clinical, and astronautical medical physician", "Considerable experience in government and highly-regulated public companies", "Roles addressing extensive and high risk conditions"] | ["GC", "STQC", "Governance", "Science, Technology and Quality"] | 2026 |
| Elizabeth A. Mily | CEO, The T1D Fund; Former EVP, Strategy & Business Development, Bristol-Myers Squibb Inc.; Director | 58 | ["CEO, The T1D Fund", "Former EVP, Strategy & Business Development, Bristol-Myers Squibb Inc.", "Extensive experience as an executive in the healthcare industry", "Significant strategy and corporate development skills", "Oversaw significant revenue growth and cost savings", "Strategic business development and partnership activities", "Numerous mergers and acquisitions experience", "Master of Science in Foreign Service from Georgetown University", "Bachelor of Arts in German Literature and European History from Ohio State University", "Fulbright Scholar to the Universities of Cologne and Hamburg"] | ["AC", "STQC", "Audit", "Science, Technology and Quality"] | 2026 |
| Glenn A. Eisenberg | Former EVP and CFO, Laboratory Corporation of America Holdings; Director | 64 | ["Former EVP and CFO, Laboratory Corporation of America Holdings", "long history as a public company finance executive", "strong audit committee expertise", "valuable experience in portfolio optimization", "Bachelor of Arts degree from Tulane University", "Master of Business Administration from Georgia State University", "audit committee financial expert", "decade of experience in healthcare services leadership", "over 20 years of experience as Chief Financial Officer and Chief Operating Officer of large public companies", "experience in driving financial performance", "senior roles at global manufacturers and healthcare companies", "valuable experience in corporate transformations", "experience streamlining operations through divestitures", "deep experience overseeing quality and compliance", "deep experience of risk management", "significant experience leading large teams and on public company boards"] | ["AC", "Audit"] | 2026 |
| John H. Weiland | Former President and COO, C.R. Bard, Inc.; Director | 70 | ["Former President and COO, C.R. Bard, Inc.", "Over 40 years of experience in leadership roles and member of multiple boards at healthcare companies", "Significant healthcare executive experience including as Chief Operating Officer of a medical technology company", "Focus on improvement in operational efficiencies across manufacturing and supply chain", "Oversight of divestitures and acquisitions to streamline product portfolio in support of margin expansion", "Service on public boards and in senior executive roles at global medical technology companies", "Responsibility in senior role for worldwide manufacturing at medical device company", "Extensive experience in guiding companies undergoing significant transitions, including significant M&A transactions", "Substantial experience at senior executive level of medical technology company", "Extensive regulatory and medical device compliance experience", "Oversaw significant business growth and revenue generation during executive tenure and as Chief Operating Officer", "Served on risk committees at public companies responsible for managing corporate and medical device risks", "Significant experience overseeing operations and on public company boards with oversight over human capital management"] | ["STQC", "Science, Technology and Quality"] | 2026 |
| Karen J. May | Former EVP and CHRO; Director | 68 | ["Former EVP and CHRO, Mondelez International, Inc.", "Significant human capital expertise", "Expertise in finance and accounting", "Experience with spin-offs, mergers and acquisitions", "Considerable experience in healthcare industry", "Substantial experience in executive leadership", "Extensive exposure to financial reporting", "Service in senior executive roles at global companies", "Experience in guiding companies through transitions", "Roles in corporate sales and marketing", "Significant experience in human capital management"] | ["TC (C)", "Talent"] | 2026 |
| Shirley Edwards | Former Global Client Service Partner, Ernst & Young Global Limited; Director | 65 | ["Deep financial and public company accounting experience", "Audit committee financial expert", "Significant experience as Chief Operating Officer for a multi-billion dollar division", "Over four decades of financial accounting and assurance experience", "Senior role at global business with oversight over 20 countries and 20,000 people", "Extensive experience in governance, finance, portfolio management and M&A transactions", "Deep knowledge of risk management, particularly financial and regulatory risk", "Senior executive leadership experience"] | ["AC*", "TC", "Audit", "Talent"] | 2026 |
| Susan D. DeVore | Former Chief Executive Officer, Premier Inc.; Director | 67 | ["Over 40 years of experience in finance, strategy, and healthcare consulting", "Executive leadership roles at a major healthcare company", "Director oversight of major acquisitions, technology implementation, and sustained growth", "Healthcare, operations, technology, and regulatory oversight knowledge"] | ["GC(C)", "Governance"] | 2026 |
